Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.
Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, Tifrea DF, Suzer B, Shaik AM, Chilukuri A, Edwards RA, Singer M, Vahed H, Nesburn AB, Kuppermann BD, Ulmer JB, Gil D, Jones TM, BenMohamed L.
Prakash S, et al. Among authors: gil d.
Front Immunol. 2024 Jan 22;15:1328905. doi: 10.3389/fimmu.2024.1328905. eCollection 2024.
Front Immunol. 2024.
PMID: 38318166
Free PMC article.